Healthcare May 11, 2022 03:53 PM (GMT+8) · EqualOcean
Yiouda health learned on May 11 that Roche announced tigit monoclonal antibody tiragolumab combined with PD-L1 monoclonal antibody atelizumab (tecentriq) ®) Interim analysis results of phase III clinical skyscraper-01 study for first-line treatment of PD-L1 overexpression locally advanced or metastatic NSCLC. The results showed that the study failed to reach the common primary endpoint of progression free survival (PFS). The other primary endpoint, overall survival (OS), is not yet mature, and Roche will continue this clinical study until the next planned data analysis. Numerical improvements were observed in the two common primary endpoints. Roche said that it would wait for OS analysis to determine the next action, and tiragolumab's clinical development plan for NSCLC and other cancer species would continue. It is reported that this is tiragolumab's second phase III clinical failure.